COVID-19 Nucleocapsid-GM-CSF Protein Lactated Ringer's Injection

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
COVID-19 Nucleocapsid-GM-CSF Protein Lactated Ringer's Injection
Accession Number
DB15845
Description

As of July 2020, Medicine Invention Design, Inc. is sponsoring a small, controlled clinical trial for the COVID-19 AP TP Vaccine for ‘proof of concept.’ The vaccine utilizes granulocyte macrophage-colony stimulating factor (GM-CSF), a cytokine known to enhance vaccine efficacy through prolongation of humoral and cell immunity.

Type
Biotech
Groups
Investigational
Synonyms
  • AP-TP-V
  • COVID-19 AP TP Vaccine
  • COVID-19 Therapeutic Vaccine - Nucleocapsid-GM-CSF Protein Lactated Ringer's Injection
External IDs
  • COVID-19 Nucleocapsid-GM-CSF Protein Lactated Ringer's Injection

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Categories

Drug Categories
Not Available
Classification
Not classified

Chemical Identifiers

UNII
Not Available
CAS number
Not Available

References

General References
  1. Yu TW, Chueh HY, Tsai CC, Lin CT, Qiu JT: Novel GM-CSF-based vaccines: One small step in GM-CSF gene optimization, one giant leap for human vaccines. Hum Vaccin Immunother. 2016 Dec;12(12):3020-3028. doi: 10.1080/21645515.2016.1221551. Epub 2016 Aug 25. [PubMed:27560197]
  2. Bonaventura A, Vecchie A, Wang TS, Lee E, Cremer PC, Carey B, Rajendram P, Hudock KM, Korbee L, Van Tassell BW, Dagna L, Abbate A: Targeting GM-CSF in COVID-19 Pneumonia: Rationale and Strategies. Front Immunol. 2020 Jul 3;11:1625. doi: 10.3389/fimmu.2020.01625. eCollection 2020. [PubMed:32719685]
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on September 17, 2020 13:08 / Updated on September 18, 2020 02:47

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates